

UC Irvine

UC Irvine Previously Published Works

Title

Ion channels: structural basis for function and disease.

Permalink

<https://escholarship.org/uc/item/39x307jx>

Journal

Seminars in perinatology, 20(6)

ISSN

0146-0005

Author

Goldstein, SA

Publication Date

1996-12-01

DOI

10.1016/s0146-0005(96)80066-8

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Ion Channels: Structural Basis for Function and Disease

Steve A. N. Goldstein

Ion channels are ubiquitous proteins that mediate nervous and muscular function, rapid transmembrane signaling events, and ionic and fluid balance. The cloning of genes encoding ion channels has led to major strides in understanding the mechanistic basis for their function. These advances have shed light on the role of ion channels in normal physiology, clarified the molecular basis for an expanding number of diseases, and offered new direction to the development of rational therapeutic interventions.

Copyright © 1996 by W.B. Saunders Company

Ion channels reside in the membranes of all cells and control their electrical activity.¹ These proteins underlie subtle biological events such as the response of a single rod cell to a beam of light, the activation of a T cell by its antigen, and the fast block to polyspermy of a fertilized ovum. They also mediate spectacular events like heart beats, systemic fluid and electrolyte homeostasis, and our memories. Over the past 40 years, increasingly sensitive electrophysiological methods have allowed characterization of channel function at remarkable resolution—single channel molecules can be observed in real time (Fig 1A). However, it is only in the last few years with the application of molecular genetic technology that we have begun to discern the structural basis for ion channel function. Cloning of genes for channels and their regulatory subunits has revealed amino acid sequences and made feasible studies of structure and function that were impossible with native tissues alone. Recent advances in our understanding of the mechanistic underpinnings for normal function of sodium (Na⁺) and potassium (K⁺) channels are discussed in this article. These insights have clarified the etiology for an expanding number of disease states and allow disorders mediated

by ion channels to be divided into two broad mechanistic groups: those resulting from loss of channel function and those consequent to gain of channel function. Three exemplary pathophysiological correlates are examined, Long QT syndrome, Liddle's syndrome and pseudohypoaldosteronism type 1 (leading to life-threatening cardiac rhythm disturbances, systemic hypertension, and hypotension, respectively). Future challenges for ion channel research are considered.

Ion Channel Function: Gating and Ion Selectivity

Ion channels perform two operations. First, they open and close in response to specific stimuli; this process is called "channel gating." Second, they catalyze the flux of specific ions across the membrane, an activity referred to as "ion selective conduction." Some channels are ligand-gated. Thus, binding of cGMP to a cyclic-nucleotide gated (CNG) channel in the retina leads to a conformational change in channel structure and a shift from a closed, nonconducting channel state to an open state that is maintained as long as cGMP is bound. Other ion channels are voltage-gated. The single Na⁺ channel shown in Fig 1A undergoes a series of state transitions when the membrane is depolarized from its resting level (−80 mV) to a more positive potential (−10 mV). The channel moves first from a closed (or resting) state to an open state that allows Na⁺ to flow into the cell; it proceeds to another nonconducting conformation, the inactive state, in which it sits silently despite maintained membrane depolarization (Fig 1B).

From the Section of Pediatric Cardiology, Department of Pediatrics and the Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT.

Supported by grants from the National Institutes of Health and the Donaghue Foundation.

Address reprint requests to Steve A. N. Goldstein, MD, PhD, Boyer Center for Molecular Medicine, Program of Molecular Cardiology, Yale University, 295 Congress Ave, New Haven, CT 06536.

*Copyright © 1996 by W.B. Saunders Company
0146-0005/96/2006-0006\$05.00/0*




Figure 1. Single channel recording of a Na⁺ channel with a gating scheme and a diagram of a cardiac action potential with two contributing channel currents. (A) Single channel recording from a cardiac voltage-gated Na⁺ channels (courtesy of Ted Cummins and Fred Sigworth, Yale University). In response to a change in voltage from -80 mV to -10 mV, the channel moves from resting to open conformation and then to an inactive state. (B) Scheme for gating of an inactivating voltage-gated channel. (C) Diagram of the phases of a cardiac Purkinje cell action potential with currents through two contributing channels superimposed, based on Fozzard.⁶⁹ The channel currents associated with the five phases of the action potential are: phase 0, rapid depolarization- I_{Na} and I_{Ca} ; phase 1, fast repolarization- I_{to} ; phase 2, plateau- I_{Ca} ; phase 3, delayed repolarization- I_{Ks} , I_{Kr} ; phase 4, pacemaker depolarization- I_{IR} , I_f .

An open ion channel forms a water-filled conduction pore across the membrane bringing the external and intracellular solutions into continuity. Ions passively diffuse through the pore in a direction determined solely by differences in ion concentration and electrical potential across the membrane. This does not indicate that channel proteins are inert scaffolding; the number and type of ions that move through a channel reveal its influence. Thus, some K⁺ channels catalyze the flow of 100,000,000 K⁺ ions each second through a single channel complex, yet maintain a preference for K⁺ over Na⁺ of 10,000 to 1.² We will consider the dramatic progress in understanding of the molecular basis for opening and inactivation of voltage-gated channels as well as the channel regions that mediate ion conduction and selectivity.

Ion Channel Function: The Cardiac Action Potential

A cell's electrical behavior is determined by the gating and selectivity attributes of its ion channels.³⁻⁵ In the heart, cells of the conduction pathway exhibit a pattern of cyclical excitability with five phases. A Purkinje cell action potential and its two primary channel currents are schematized in Fig 1C. Phase 0 is an explosive rise in membrane potential due to a rush of Na⁺ into the cell (down its concentration gradient) through voltage-gated Na⁺ channels that open with membrane depolarization; these channels then rapidly inactivate (Fig 1A, B). Phase 1 is a brief repolarization step mediated by voltage-gated K⁺ channels that open with depolarization and, like phase 0 Na⁺ channels, rapidly inactivate. Because outward flow of K⁺ (down its concentration gradient) makes the cell interior more negative, opening K⁺ channels shifts the cell toward more negative potentials. Phase 2, the plateau in the action potential, is coincident with myocardial contraction and results from the cumulative activity of a number of channel and carrier-type transporters. The duration of phase 2 is determined by voltage-gated K⁺ channels that open with a delay in response to membrane depolarization and remain open until the membrane is again hyperpolarized (Fig 1C). These delayed outward K⁺ currents return the membrane to its resting potential during phase 3 and

allow the heart to relax. Phase 4, the pacemaker potential, is a slow rise in membrane potential attributed to closing of other K^+ channels and instigates the next cycle of excitation and contraction. In broad outline, cardiac excitation results from rapid, voltage-dependent gating of Na^+ channels, delayed, voltage-dependent gating of K^+ channels, and the ability of both channels to discriminate between Na^+ and K^+ ions.

Cloning of Genes Encoding Ion Channels

Identification of the structural determinants of gating and selectivity followed cloning of the genes encoding ion channels. The first Na^+ channel gene was isolated by a direct biochemical approach; channel protein was purified from the electric organ of the *Electrophorus electricus* eel in sufficient quantity to allow production of anti-channel antibodies, and these were subsequently used to screen and isolate the gene from an eel cDNA expression library.⁶ K^+ channels have no high abundance tissue source; the first K^+ channel gene was isolated after its identification as the cause of a motion disorder in mutant fruit flies.⁷⁻⁹ Scores of related Na^+ and K^+ channel genes and their human homologues were then identified based on their homology to the sequences of these first two genes.¹⁰ More recently, novel ion channel genes have been isolated by screens for expression of channel function rather than DNA sequence homology¹¹⁻¹⁴ and by computer analysis of the rapidly expanding database of genomic and expressed nucleotide sequences for channel-like motifs.^{15,16}

Classification of Ion Channels by Structure

Once genes for voltage-gated Na^+ , Ca^{2+} , and K^+ channels and ligand-gated CNG channels were isolated, their membership in an extended molecular superfamily was revealed. Marked by similarities in primary sequence and predicted membrane topology, voltage-gated Na^+ and Ca^{2+} channels contain four homologous domains in tandem, each with six predicted membrane-spanning segments (Fig 2A). Voltage-gated K^+ channel subunits and CNG channel subunits are similar in size and topology to a single Na^+ channel domain (Fig 2B). Inward rectifier K^+ chan-

nels and epithelial Na^+ channels share a proposed two transmembrane topology (Fig 2C), whereas the recently identified outward rectifier (Fig 2D) and open rectifier K^+ channel subunits (Fig 2E) are built with two domains similar to those observed in previously identified K^+ channels.

Assigning Structure to Function: Voltage-Dependent Gating

Channel regions that participate in gating and ion selectivity were first suggested by comparison of the amino acid sequences predicted from each newly isolated gene.^{6,17,18} Candidate regions were then evaluated and influential residues identified by studying the functional effects of site-directed mutations.

Resting to Open Transition

Hodgkin and Huxley³ first proposed that changes in voltage might cause the movement of charged "gating particles" within nerve membranes to turn Na^+ and K^+ conductances on and off. Thirty years later, cloning revealed that voltage-gated channels carry a novel charge-containing motif not observed before in membrane proteins: at every third or fourth position in the fourth predicted transmembrane segments (S4), a positive arginine or lysine residue is present. That movement of these S4 charges might mediate the effects of voltage on channel activation gained early support^{19,20} and has now been firmly established.^{21,22}

Yang et al^{21,23} investigated the S4 segment in the fourth homologous domain (D4) of a human skeletal muscle voltage-gated Na^+ channel. They started with a channel mutant, first identified in patients with paramyotonia congenita,²⁴ in which the initial arginine in S4/D4 is mutated to cysteine. When they added a cysteine-specific reagent to the external solution, the channel became covalently modified and its gating was changed. Modification was speeded by membrane depolarization as if voltage caused outward movement of the S4/D4 segment and greater exposure of the cysteine to reagent in the bath. Study of each of the seven remaining positively charged S4/D4 residues supported the hypothesis that this region held the long-sought




Figure 2. Probable membrane topologies of ion channel α -subunits. (A) Voltage-gated Na^+ and Ca^{2+} channels; (B) voltage-gated K^+ channels and CNG-gated channels; (C) inward rectifier K^+ channels and epithelial Na^+ channels; (D) two P domain outward rectifier K^+ channel^{15,16}; and (E) two P domain open rectifier K^+ channel.¹⁴

gating particles²¹; whereas wild-type channels were unaffected by cysteine-specific probes, channels with cysteine at the 1st, 2nd, or 3rd charged site altered gating. Notably, the second and third sites were modified only under some circumstances: *external* reagent had no effect if the membrane was hyperpolarized (and channels were at rest), but acted on depolarization; moreover, *internal* reagent had no effect if the membrane was depolarized, but acted on hyperpolarization. These sites seemed to move completely across the membrane; exposed inside the membrane at rest, they gained exposure to the external solution with depolarization.

How gating charge movements are translated into channel opening is not yet known. However, a hypothesis for the channel's structure near S4 suggests that the first three charged sites move into continuity with the external solution (or into a vestibule large enough to accommodate the cysteine probes which are $\sim 6^\circ\text{A}$ in diameter), whereas the fourth charged site remains exposed to the internal compartment. In α -helical conformation, the third and fourth sites could be separated by as little as 4.5°A (if extended, by no more than 10 to 11°A). Thus, gating charges seem to travel through short canals

(canaliculi) in the protein to reach vestibules in contact with cellular or external solution and, thereby, limit their unfavorable interaction with membrane lipids (Fig 3A).²⁵ This suggests how gating charges move completely across 40°A of hydrophobic cell membrane in just a few 10 millionths of a second: only some S4 charges traverse the membrane, and their movement is over a limited distance. A similar model for the role of the S4 in voltage-gated K^+ channel function has been cogently argued.²⁶

Open to Inactive Transition

The inrush of Na^+ in phase 0 of the cardiac action potential is explosive and regenerative because Na^+ influx drives the membrane to more positive potentials, leading even more voltage-gated Na^+ channels to open. The process is restrained by transition of the channels to an inactive state a few milliseconds after they open (Fig 1A). Armstrong and Bezanilla first proposed a "ball and chain" model for fast inactivation based on their observation that internal protease treatment produced channels that did not inactivate.²⁷ They suggested that protease removed a portion of the channel (the ball) that moved into the channel pore after it was open to physi-

cally block ion conduction (Fig 3B). In fact, this simple mechanism seems to be operative in both K^+ and Na^+ channels. In Shaker K^+ channels, the intracellular amino-terminus of the protein functions as a tethered open channel blocker.^{28,29} When these residues are removed by protease treatment (or by genetic deletion), the channels no longer show fast inactivation. Remarkably, application of the deleted "inactivation ball" as a soluble peptide to the intracellular face of the channel restores inactivation. Moreover, varying the length of the "chain" of residues between the "ball" and the rest of the channel varies the speed of inactivation. In Na^+ channels, it is the cytoplasmic residues linking homologous domains III and IV that are critical for fast inactivation and function to block open channels.^{19,30,31} This was shown first by inhibition of inactivation by internally applied peptide-specific antibodies and, subsequently, by site-directed mutation. Deletion of residues mediating fast inactivation often reveals a slow inactivation process that proceeds over 100's of milliseconds and is mediated by the S5, P, and S6 domains in K^+ channels.³²

Accessory Subunits

The core (or α) subunits depicted in Fig 2 can function by themselves; however, in most cells they are expressed in association with one or more accessory subunits. These additional subunits are essential to integrated cellular function. They regulate channel expression levels, modify functional activity, and influence pharmacological sensitivity. Some accessory subunits carry an inactivation ball and produce rapidly inactivating channels when assembled with K^+ channel α -subunits that normally remain open with maintained depolarization. For an excellent recent review, see Catterall.³³

Assigning Structure to Function: Ion Selectivity

Voltage-gated Na^+ , Ca^{2+} , and K^+ channels and CNG channels show fourfold symmetry. In each, a single conduction pore is formed, either through folding of four homologous domains, or aggregation of four independent subunits. The residues linking every fifth and sixth mem-




Figure 3. Schematic representations of channel structures involved in channel gating and pore formation. (A) The S4 segment of the Na^+ channel fourth homologous domain is diagrammed indicating the proposed relationship of the gating charges to the S4 canalculus in the resting and open conformations, based on reference 21; (B) the "ball and chain" model of K^+ channel inactivation suggests the amino-terminal residues act as a tethered blocker that enters and occludes the internal channel vestibule after the channel is open, based on references 28 and 29. (C) The amino acids in the S5-S6 linker region of the Shaker K^+ channel that are pore-forming are indicated by their single letter codes; residues that are critical to charybdotoxin binding have an asterisk (*), the sites critical to external tetraethylammonium ion (TEA) binding are outlined; a site critical to internal TEA binding is underlined; the P domain "signature sequence" residues are bolded.

brane-spanning segment contribute to pore formation (P domains; Fig 2) and are arrayed centrally as four "pore loops".³⁴ Pores are the catalytic "active sites" of ion channels, and identification of P domains has been a major recent step in understanding the structural basis for channel function.^{18,35-38}

The first clue to which residues formed the pore in K⁺ channels came from studies of blockade of Shaker K⁺ channels by the scorpion venom neurotoxin, charybdotoxin. Previously, functional studies had indicated that charybdotoxin interacted with negatively charged sites on K⁺ channels and inhibited by physically occluding the external pore entryway.³⁹⁻⁴¹ Now, systematic point mutation of negative residues in Shaker revealed that a unique glutamate residue in the channel region linking transmembrane stretches S5 and S6 was one such interaction site and was probably near the channel pore³⁵; residues across this S5-S6 linker region were subsequently shown to be critical to toxin binding (Fig 3C).⁴²⁻⁴⁴

That the S5-S6 linker crossed the membrane to form the ion conduction pathway was shown by identification of two binding sites in this region for tetraethylammonium ion (TEA), one extracellular and one intracellular.^{36,37} This was a surprising result because hydropathy analysis had suggested the region was likely to form a completely extracellular protein loop. In dramatic support for this model, a chimeric channel with 24 of its S5-S6 linker residues replaced by linker sites from another channel showed pore characteristics of the donor channel; the chimera showed high single channel conductance (unlike the native channel), high sensitivity to internal TEA (rather than low), and low sensitivity to external TEA (rather than high).³⁸ Notably, 2 years in advance of any of these experimental findings, evaluation of the Na⁺ channel sequence had led Guy and Seetharamulu to propose from first principles that the residues linking S5 and S6 would dip into the membrane to form the pore.¹⁸ Comparison of sequences of cloned K⁺ channels and detailed studies of channels with point mutations in the P domain allowed Heginbotham et al to identify a "signature sequence" of eight highly conserved residues in the P domains of all K⁺-selective ion channels (Fig 3C).^{45,46}

Although membrane proteins like channels are not yet readily amenable to crystallization and direct structural determination, peptide toxins have provided an indirect means to assess spatial locations of pore residues. This has been achieved by combining the known three-dimensional structure of the toxins and identified sites of toxin-channel interaction.^{47,48} From a first crude image of the Shaker K⁺ channel vestibule using charybdotoxin and a first weak contact pair,⁴⁴ a sixth coupling pair and the largest interaction energy yet observed was recently reported.⁴⁹ The significance of that report lies in the fact that the contact was predicted from a pair-driven model of the pore and, so, validated its conclusions.

Channel Heterogeneity

The large variety of channel currents observed in vivo results first from the many separate genes encoding pore-forming channel subunits. This diversity is increased by alternative RNA splicing⁵⁰ and RNA editing,^{51,52} which modify the encoded primary structure of the core subunits after transcription. Diversity is even more pronounced in channels that form as multimeric complexes because subunits can associate in varied combinations. Thus, voltage-gated K⁺ channels assemble either as homotetramers or as heteromeric mixtures of two or more subunit types. Heteromeric channels exhibit new characteristics in gating, conduction, and pharmacology⁵³; some, like cardiac K_{ACh} channels, require heteromeric association to form functional channel complexes.⁵⁴ Another degree of functional diversity is provided by modulatory accessory subunits that associate with the pore-forming core subunits.

Regulation of Channel Function

Channels are regulated in a cell-by-cell fashion; thus, adjacent cells in a tissue can express different channels or channel subtypes; for an excellent review see Levitan and Kaczmarck.⁵⁵ Specificity is achieved at multiple levels: which core and accessory subunits are expressed is controlled at the level of gene transcription, RNA editing, and RNA translation. Variation in channel levels and subtypes is observed with develop-

Table 1. Diseases Mediated by Ion Channels

<i>Mechanism</i>	<i>Disease</i>	<i>Channel</i>	<i>Reference</i>
Loss of function			
Low levels of surface expression			
Unstable protein	Cystic fibrosis	CFTR	70, 71
Autoimmune degradation	Myasthenia gravis	AchR	72
	Lambert-Eaton syndrome	VGCa	73
	Acquired myotonia	VGK	74
Open poorly, inactivate quickly	PHHI	K _{ATP}	75
	Thomsen's myotonia	CLC-1	76
	Becker's myotonia		
Decreased single channel conductance	Cystic fibrosis	CFTR	77
Channel down-regulation	Cystic fibrosis	CFTR	78
Decreased agonist affinity	Myasthenic syndrome-LAFC	AChR	79
Blockade by drugs or poisons	Long QT syndrome	HERG	60
Altered channel selectivity	Weaver mice	VGK	58
No channel function-undetermined	Dent's disease, XRN, XLRH	CLC-5	80
	PHA-1	α -ENaC	65
Gain of function			
Open too readily	HYPP	SCN4a	81
Inactivate slowly	Paramyotonia congenita	SCN4a	81
	Long QT syndrome	SCN5a	82
High open probability	Liddle's syndrome	ENaC	62, 63
	Malignant hyperthermia	RYR	83, 84
Activated by drugs or poisons	Cholinesterase inhibitors	AChR	85
Channel up-regulation	Neuronal cell death in stroke	NMDA	86

Abbreviations: CFTR, cystic fibrosis transmembrane regulator; AChR, acetylcholine receptor channel; VGCa, voltage-gated calcium channel; VGK, voltage-gated potassium channel; PHHI, persistent hyperinsulinemic hypoglycemia of infancy; K_{ATP}, ATP sensitive potassium channel; CLC1, voltage-gated chloride channel type 1; HERG, human eag-related gene, a voltage-gated K⁺ channel; XRN, X-linked recessive nephrolithiasis; XLRH, X-linked recessive hypophosphatemic rickets; PHA-1, pseudohypoaldosteronism type 1; LAFC, low-affinity, fast channel congenital myasthenic syndrome; HYPP, hyperkalemic periodic paralysis; SCN4a, a human skeletal muscle voltage-gated sodium channel; SCN5a, a human cardiac voltage-gated Na⁺ channel; ENaC, epithelial Na⁺ channel; RYR, Ryanodine receptor, a calcium release channel; NMDA, N-methyl-D-aspartate receptors, calcium channels.

mental stage, cell cycle, and external stimulation. Moreover, some channels are accurately localized to defined subcellular sites (such as motor end plates or dendrites), whereas others are sorted to apical or basolateral surfaces in polarized cells to achieve vectorial transport. Many channels are also subject to strict modulation by second messenger levels or by direct phosphorylation.^{56,57} These mechanisms underlie a diverse repertoire of ion channel functions observed in normal cellular physiology.

Channel Dysfunction and Disease

As the molecular basis for ion channel function has been revealed, so has the basis for an increasing number of ion channel-mediated diseases. Table 1 categorizes disorders of known etiology

into two groups: those resulting from loss of channel function and those due to gain of channel function. Loss of function can be a result of low levels of channel protein in the membrane. Thus, the most common variant of cystic fibrosis is marked by inherent instability of the CFTR Δ 508 chloride channel protein leading to its rapid intracellular degradation. Autoantibodies mediate channel degradation in myasthenia gravis, Lambert-Eaton syndrome, and one form of acquired myotonia (Table 1). Loss of function disorders are also observed when channels reach the membrane but show decreased activity. Examples in humans include persistent hyperinsulinemic hypoglycemia of infancy (PHHI) and the inherited congenital myotonias (Thomsen's, Becker's) in which channels open poorly or for too short a time. Other loss of function disorders are the result of decreased single channel con-

ductance, inappropriate down-regulation, decreased agonist affinity, and blockade by drugs or poisons (Table 1). *Weaver* mice have a neurodegenerative disorder characterized by K^+ channels that open but are no longer selective.⁵⁸ Not yet reported for ion channels are diseases resulting from diminished transcription and translation or rapid degradation owing to improper secondary modification.

Disorders resulting from a gain of channel function include hyperkalemic periodic paralysis (HYPP) in which channels open too readily, and paramyotonia congenita (PC) in which they inactivate too slowly. Other gain of function diseases are due to channels that have an abnormally high open probability as a result of mutations or exogenous activation by drugs or poisons (Table 1). The pathophysiology of neuronal cell death in stroke seems to involve dysfunctional up-regulation of NMDA Ca^{2+} channels (Table 1). No disorders are yet known to result from protein overproduction, diminished degradation, or increased single channel conductance. An excellent review of hereditary diseases of skeletal muscle ion channels is published.⁵⁹

Correlation of Channel Function and Disease: Three Examples

Long QT syndrome (LQTS) is a cardiac disorder that predisposes the heart to torsade de pointes, a ventricular arrhythmia that can degenerate into ventricular fibrillation and cause sudden death. It can be acquired, most commonly as a side effect of treatment with class IA or III antiarrhythmic medications, or inherited. The electrocardiograms of affected individuals show an abnormally prolonged repolarization interval (QT_c). Recent molecular studies have established that two forms of inherited LQTS result from mutations in the genes encoding cardiac ion channels. SCN5a on chromosome 3 encodes the cardiac voltage-gated Na^+ channel that underlies the rapid rising phase of the cardiac action potential (Fig 1B, phase 0). Mutations in SCN5a produce channels with destabilized inactivation gates. Mutant channels open normally, but are not stable in the inactivated state; by reopening repetitively during depolarization, the channels prolong the cardiac action poten-

tial. A different mechanism underlies LQTS resulting from mutation in the human eag-related gene (HERG) locus on human chromosome 7. HERG encodes the core subunit of a K^+ channel and mediates a cardiac delayed-rectifier K^+ current, I_{Kr} critical to myocardial action potential repolarization (Fig 1B, phase 3). A number of mutations in HERG channels have now been identified in individuals with LQTS: all act to reduce channel function and prolong action potential duration. Drug-induced LQTS also results from decreased HERG channel function but is due to channel blockade.⁶⁰ These mechanistic insights have facilitated new therapeutic approaches. LQTS resulting from mutations in SCN5a (gain of function) has proven amenable to treatment with Na^+ channel blockers, whereas individuals with mutations in HERG (loss of function) have corrected their repolarization abnormalities in response to modest increases in extracellular K^+ concentration.⁶¹

Liddle's syndrome (pseud aldosteronism) is an autosomal dominant disorder characterized by early onset of moderate to severe hypertension. Lifton and colleagues recently showed that this disorder results from mutations in subunits of the amiloride-sensitive epithelial Na^+ channel (ENaC) of the kidney and that mutations lead to constitutive channel activation (gain of function).⁶²⁻⁶⁴ These channels are formed by co-assembly of α , β , and γ subunits. Affected patients have been found to carry mutations that lead to deletion of the cytoplasmic carboxyl termini of their β or γ ENaC subunits. Biophysical analysis of one β subunit mutation revealed channels with normal single channel conductance, ion selectivity and sensitivity to amiloride blockade, but excess channel openings in membrane patches. Because reabsorption of Na^+ through ENaC is regulated by aldosterone, a process that is a major determinant of net Na^+ reabsorption by the kidney, increased channel activity leads to increased Na^+ reabsorption and hypertension in affected individuals.

Autosomal recessive pseudohypoaldosteronism type 1 (PHA-1) is characterized by life-threatening dehydration in the neonatal period. It is characterized by marked hypotension, salt wasting, elevated K^+ levels, metabolic acidosis, and marked elevation in plasma renin and aldosterone levels. In this case, Lifton and colleagues

showed the disorder to result from mutations in α or β ENaC subunits leading to loss of channel function.⁶⁵ ENaC dysfunction seems to cause the disorder by facilitating renal tubular Na^+ loss. This leads to a secondary defect in secretion of K^+ and H^+ ions and stimulation of the renin-angiotensin system. However, salt reabsorption is not increased because the ENaC target is unresponsive.

Future Research Directions

An array of medical conditions are potentially amenable to treatment by agents that act on ion channels.⁶⁶ Abnormal ion channels are directly responsible for the pathophysiology of some diseases. In other cases, normal ion channels are inappropriately regulated. To develop rational therapeutic interventions targeted at ion channels, a series of unanswered queries lies ahead. Recognized currents that are key to tissue function must be identified at the molecular level (for example, the I_f current that mediates cardiac pacemaker function^{67,68}). The biochemical rules that govern subunit association must be defined. The constituent subunits of heteromeric complexes that mediate function in vivo need to be delineated. The pattern of functional expression of channel subtypes through development needs to be described. Regulation and modulation of ion channel function in vivo remain poorly elucidated. To understand the structural basis for channel function, accurate three-dimensional information about the structure of ion channels is required. It seems likely that the mechanisms of most channel-mediated disorders are yet to be discerned, and that many diseases are yet to be appropriately attributed to ion channel dysfunction. To achieve therapies based on mechanistic insight, we have many barriers to surmount. The rapid progress made in the last few years makes such a goal seem feasible.

References

- Hille B: Ionic Channels of Excitable Membranes, 2nd ed. Sunderland, MA, Sinauer, 1992
- Yellen G: Ionic permeation and blockade in Ca^{2+} -activated K^+ channels of bovine chromaffin cells. *J Gen Physiol* 84:157-186, 1984
- Hodgkin AL, Huxley AF: A quantitative description of membrane current and its application to conduction and excitation in nerve. *J Physiol* 117:500-544, 1952
- Fozzard HA, Makielski JC: The electrophysiology of acute myocardial ischemia. *Ann Rev Med* 36:275-284, 1985
- Sanguinetti MC, Jurkiewicz NK: Two components of cardiac delayed rectifier K^+ current. Differential sensitivity to block by class III antiarrhythmic agents. *J Gen Physiol* 96:195-215, 1990
- Noda M, Shimizu S, Tanabe T, et al: Primary structure of *Electrophorus electricus* sodium channel deduced from cDNA sequence. *Nature* 312:121-127, 1984
- Papazian DM, Schwarz TL, Tempel BL, et al: Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from *Drosophila*. *Science* 237:749-753, 1987
- Pongs O, Kecskemethy N, Muller R, et al: Shaker encodes a family of putative potassium channel proteins in the nervous system of *Drosophila*. *EMBO J* 7:1087-1096, 1988
- Iverson LE, Tanouye MA, Lester HA, et al: A-type potassium channels expressed from Shaker locus cDNA. *Proc Natl Acad Sci USA* 85:5723-5727, 1988
- Chandy KG, Gutman GA: Nomenclature for mammalian potassium channel genes. *Trends Pharmacol Sci* 14:434, 1993
- Ho K, Nichols CG, Lederer WJ, et al: Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. *Nature* 362:31-38, 1993
- Kubo Y, Reuveny E, Slesinger PA, et al: Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. *Nature* 364:802-806, 1993
- Canessa CM, Schild L, Buell G, et al: Amiloride-sensitive epithelial Na^+ channel is made of three homologous subunits [see comments]. *Nature* 367:463-467, 1994
- Goldstein SAN, Price LA, Rosenthal DN, Pausch MH: A potassium-selective leak channel with two pore domains cloned from *Drosophila melanogaster* by expression in *Saccharomyces cerevisiae*, ORK1. *Proc Natl Acad Sci* 93:13256-13261, 1996
- Ketchum KA, Joiner WJ, Sellers AJ, et al: A new family of outwardly-rectifying potassium channel proteins with two pore domains in tandem. *Nature* 376:690-695, 1995
- Lesage F, Guillemare E, Fink M, et al: TWIK-1, a ubiquitous human weakly inward rectifying K^+ channel with a novel structure. *EMBO* 15:1004-1011, 1996
- Catterall WA: Molecular properties of voltage-sensitive sodium channels. *Ann Rev Biochem* 55:953-985, 1986
- Guy HR, Seetharamulu P: Molecular model of the action potential sodium channel. *Proc Natl Acad Sci USA* 83:508-512, 1986
- Stuhmer W, Conti F, Suzuki H, et al: Structural parts involved in activation and inactivation of the sodium channel. *Nature* 339:597-603, 1989
- Papazian DM, Timpe LC, Jan YN, Jan LY: Alteration of voltage-dependence of Shaker potassium channel by mutations in the S4 sequence. *Nature* 349:305-310, 1991
- Yang N, George Jr. AL, Horn R: Molecular basis of charge movement in voltage-gated sodium channels. *Neuron* 16:113-122, 1996

22. Larsson HP, Baker OS, Dhillon DS, Isacoff EY: Transmembrane movement of the Shaker K⁺ channel S4. *Neuron* 16:387-397, 1996
23. Yang N, Horn R: Evidence for voltage-dependent S4 movement in sodium channels. *Neuron* 15:213-218, 1995
24. Ptacek LJ, George Jr. AL, Barchi RL, et al: Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita. *Neuron* 8:891-897, 1992
25. Goldstein SAN: A structural vignette common to voltage sensors and conduction pores: Canaliculi. *Neuron* 16:717-722, 1996
26. Manuzzu LM, Moronne MM, Isacoff EY: Direct physical measure of conformational rearrangement underlying potassium channel gating. *Science* 271:213-216, 1996
27. Armstrong CM, Bezanilla F: Inactivation of the sodium channel. II. Gating current experiments. *J Gen Physiol* 70:567-590, 1977
28. Zagotta WN, Hoshi T, Aldrich RW: Restoration of inactivation in mutants of Shaker potassium channels by a peptide derived from ShB [see comments]. *Science* 250:568-571, 1990
29. Hoshi T, Zagotta WN, Aldrich RW: Biophysical and molecular mechanisms of Shaker potassium channel inactivation. *Science* 250:533-538, 1990
30. Vassilev P, Scheuer T, Catterall WA: Inhibition of inactivation of single sodium channels by a site-directed antibody. *Proc Natl Acad Sci USA* 86:8147-8151, 1989
31. West JW, Patton DE, Scheuer T, et al: A cluster of hydrophobic amino acid residues required for fast Na⁺-channel inactivation. *Proc Natl Acad Sci USA* 89:10910-10914, 1992
32. Yellen G, Sodickson D, Chen TY, Jurman ME: An engineered cysteine in the external mouth of a K⁺ channel allows inactivation to be modulated by metal binding. *Biophys J* 66:1068-1075, 1994
33. Catterall WA: Structure and function of voltage-gated ion channels. *Ann Rev Biochem* 64:493-531, 1995
34. MacKinnon R: Pore loops: An emerging theme in ion channel structure. *Neuron* 14:889-892, 1995
35. MacKinnon R, Miller C: Mutant potassium channels with altered binding of charybdotoxin, a pore-blocking peptide inhibitor. *Science* 245:1382-1385, 1989
36. MacKinnon R, Yellen G: Mutations affecting TEA blockade and ion permeation in voltage-activated K⁺ channels. *Science* 250:276-279, 1990
37. Yellen G, Jurman ME, Abramson T, MacKinnon R: Mutations affecting internal TEA blockade identify the probable pore-forming region of a K⁺ channel. *Science* 251:939-942, 1991
38. Hartmann HA, Kirsch GE, Drewe JA, et al: Exchange of conduction pathways between two related K⁺ channels. *Science* 251:942-944, 1991
39. Anderson CS, MacKinnon R, Smith C, Miller C: Charybdotoxin block of single Ca²⁺-activated K⁺ channels. Effects of channel gating, voltage, and ionic strength. *J Gen Physiol* 91:317-333, 1988
40. MacKinnon R, Miller C: Mechanism of charybdotoxin block of the high-conductance, Ca²⁺-activated K⁺ channel. *J Gen Physiol* 91:335-349, 1988
41. Miller C: Competition for block of a Ca²⁺-activated K⁺ channel by charybdotoxin and tetraethylammonium. *Neuron* 1:1003-1006, 1988
42. MacKinnon R, Heginbotham L, Abramson T: Mapping the receptor site for charybdotoxin, a pore-blocking potassium channel inhibitor. *Neuron* 5:767-771, 1990
43. Goldstein SA, Miller C: A point mutation in a Shaker K⁺ channel changes its charybdotoxin binding site from low to high affinity. *Biophys J* 62:5-7, 1992
44. Goldstein SA, Pheasant DJ, Miller C: The charybdotoxin receptor of a Shaker K⁺ channel: Peptide and channel residues mediating molecular recognition. *Neuron* 12:1377-1388, 1994
45. Heginbotham L, Abramson T, MacKinnon R: A functional connection between the pores of distantly related ion channels as revealed by mutant K⁺ channels. *Science* 258:1152-1155, 1992
46. Heginbotham L, Lu Z, Abramson T, MacKinnon R: Mutations in the K⁺ channel signature sequence. *Biophys J* 66:1061-1067, 1994
47. Miller C: The charybdotoxin family of K⁺ channel-blocking peptides. *Neuron* 15:5-10, 1995
48. Aiyar J, Withka JM, Rizzi JP, et al: Topology of the pore-region of a K⁺ channel revealed by the NMR-derived structures of scorpion toxins. *Neuron* 15:1169-1181, 1995
49. Naranjo D, Miller C: A strongly interacting pair of residues on the contact surface of charybdotoxin and a shaker K⁺ channel. *Neuron* 16:123-130, 1996
50. Lagrutta A, Shen KZ, North RA, Adelman JP: Functional differences among alternatively spliced variants of Slowpoke, a *Drosophila* calcium-activated potassium channel. *J Biol Chem* 269:20347-20351, 1994
51. Egebjerg J, Kukekov V, Heinemann SF: Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence. *Proc Natl Acad Sci USA* 91:10270-10274, 1994
52. Melcher T, Maas S, Higuchi M, et al: Editing of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR-B pre-mRNA in vitro reveals site-selective adenosine to inosine conversion. *J Biol Chem* 270:8566-8570, 1995
53. Ruppersberg JP, Schroter KH, Sakmann B, et al: Heteromultimeric channels formed by rat brain potassium-channel proteins [see comments]. *Nature* 345:535-537, 1990
54. Krapivinsky G, Gordon EA, Wickman K, et al: The G-protein-gated atrial K⁺ channel IKACH is a heteromultimer of two inwardly rectifying K⁺-channel proteins. *Nature* 374:135-141, 1995
55. Levitan IB, Kaczmarek LK: *The Neuron: Cell and Molecular Biology*, 2nd ed. New York, NY, Oxford University Press, 1996
56. Wilson GF, Kaczmarek LK: Mode-switching of a voltage-gated cation channel is mediated by a protein kinase A-regulated tyrosine phosphatase. *Nature* 366:433-438, 1993
57. Levitan IB: Modulation of ion channels by protein phosphorylation and dephosphorylation. *Annu Rev Physiol* 56:193-212, 1994
58. Kofuji P, Hofer M, Millen KJ, et al: Functional analysis

- of the weaver mutant GIRK2 K⁺ channel and rescue of weaver granule cells. *Neuron* 16:941-952, 1996
59. George AL Jr: Molecular genetics of ion channel diseases. *Kidney Int* 48:1180-1190, 1995
 60. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the I_{Kr} potassium channel. *Cell* 81:299-307, 1995
 61. Keating MT, Sanguinetti MC: Molecular genetic insights into cardiovascular disease. *Science* 272:681-685, 1996
 62. Shimkets RA, et al: Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. *Cell* 79:407-414, 1994
 63. Schild L, Canessa CM, Shimkets RA, et al: A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the *Xenopus laevis* oocyte expression system. *Proc Natl Acad Sci USA* 92:5699-5703, 1995
 64. Hansson JH, Nelson-Williams C, Suzuki H, et al: Hypertension caused by a truncated epithelial sodium channel gamma subunit: Genetic heterogeneity of Liddle syndrome. *Nature Genet* 11:76-82, 1995
 65. Chang SS, Grunder S, Hanukoglu A, et al: Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type I. *Nat Genet* 12:248-253, 1996
 66. Goldstein SAN, Colatsky TJ: Ion channels: Too complex for rational drug design? *Neuron* 16:913-919, 1996
 67. Yanigihara K, Irisawa H: Inward current activated during hyperpolarization in the rabbit sinoatrial node cell. *Pflügers Arch* 385:11-19, 1980
 68. Yu H, Chang F, Cohen IS: Pacemaker current exists in ventricular myocytes. *Circ Res* 72:232-236, 1993
 69. Fozzard HA: Cardiac electrogenesis and the sodium channel, in Spooner PM, et al (eds): *Ion Channels in the Cardiovascular System*. Armonk, NY, Futura Publishing Co., 1994, pp 81-99
 70. Riordan JR, Rommens JM, Kerem B, et al: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA [published erratum appears in *Science* 245:1437, 1989]. *Science* 245:1066-1073, 1989
 71. Denning GM, Anderson MP, Amara JF, et al: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive [see comments]. *Nature* 358:761-764, 1992
 72. Zisman E, Katz-Levy Y, Dayan M, et al: Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. *Proc Natl Acad Sci USA* 93:4492-4497, 1996
 73. Takamori M, Takahashi M, Yasukawa Y, et al: Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. *J Neurol Sci* 133:95-101, 1995
 74. Vincent A, Roberts M, Willison H, et al: Autoantibodies, neurotoxins and the nervous system. *J Physiol Paris* 89:129-136, 1995
 75. Thomas PM, Cote GJ, Wohlk N, et al: Mutations in the sulfonyleurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. *Science* 268:426-429, 1995
 76. Koch MC, Steinmeyer K, Lorenz C, et al: The skeletal muscle chloride channel in dominant and recessive human myotonia. *Science* 257:797-800, 1992
 77. Sheppard DN, Rich DP, Ostedgaard LS, et al: Mutations in CFTR associated with mild-disease-form Cl⁻ channels with altered pore properties [see comments]. *Nature* 362:160-164, 1993
 78. Li M, McCann JD, Anderson MP, et al: Regulation of chloride channels by protein kinase C in normal and cystic fibrosis airway epithelia. *Science* 244:1353-1356, 1989
 79. Ohno K, Wang H-L, Milone M, et al: Congenital myasthenic syndrome caused by decreased agonist affinity due to a mutation in the acetylcholine receptor ϵ subunit. *Neuron* 17:157-170, 1996
 80. Lloyd SE, Pearce SH, Fisher SE, et al: A common molecular basis for three inherited kidney stone diseases. *Nature* 379:445-449, 1996
 81. Yang N, Ji S, Zhou M, et al: Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. *Proc Natl Acad Sci USA* 91:12785-12789, 1994
 82. Bennett PB, Yazawa K, Makita N, George, Jr. AL: Molecular mechanism for an inherited cardiac arrhythmia. *Nature* 376:683-685, 1995
 83. Gillard EF, Otsu K, Fujii J, et al: Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. *Genomics* 13:1247-1254, 1992
 84. Shomer NH, Louis CF, Fill M, et al: Reconstitution of abnormalities in the malignant hyperthermia-susceptible pig ryanodine receptor. *Am J Physiol* 264:C125-135, 1993
 85. Millard CB, Broomfield CA: Anticholinesterases: Medical applications of neurochemical principles. *J Neurochem* 64:1909-1918, 1995
 86. Mody I, MacDonald JF: NMDA receptor-dependent excitotoxicity: The role of intracellular Ca²⁺ release. *Trends Pharmacol Sci* 16:356-359, 1995